Overview of Dr. Agrawal
Dr. Vaibhav Agrawal, based in Duarte, CA, specializes in Hematology with subspecialties in Hematologic Oncology and Myeloproliferative Disorder Hematology-Oncology. He completed his Hematology Fellowship in 2021 at Stanford Health Care and holds an MD from Chicago Medical School. His employment history includes Research Associate at Helford Clinical Research Hospital and Assistant Clinical Professor at City of Hope, along with fellowships at Stanford University School of Medicine and Indiana University Health University Hospital. His experience covers immunotherapy, hematologic oncology, hematopoietic stem cell transplantation, bone marrow transplantation, and acute myeloid leukemia. Dr. Agrawal has several publications on topics relating to his field.
Office
Department of Hematology & HCT
1500 East Duarte Road
Duarte, CA 91010Fax+1 626-389-3058- Is this information wrong?
Education & Training
- Stanford Health Care-Sponsored Stanford UniversityFellowship, Hematology, 2021
- Indiana University School of MedicineFellowship, Hematology and Medical Oncology, 2017 - 2020
- Geisinger Health SystemResidency, Internal Medicine/Pediatrics, 2013 - 2017
- Loyola University Chicago School of LawM.J., Health Care Law, 2011 - 2015
- Chicago Medical School at Rosalind Franklin University of Medicine and ScienceClass of 2013, MD
- Loyola University ChicagoM.B.A., Healthcare Management, 2009 - 2011
- Rosalind Franklin University College of Health ProfessionsM.S., Health Care Administration, 2008 - 2011
Certifications & Licensure
- CA State Medical License 2020 - 2026
- IL State Medical License 2024 - 2026
- IN State Medical License 2018 - 2021
- PA State Medical License 2013 - 2017
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant Start of enrollment: 2024 Aug 30
Roles: Contact, Principal Investigator
- Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory Start of enrollment: 2020 May 04
- A Study of Subcutaneous Blinatumomab Administration in Acute Lymphoblastic Leukemia (ALL) Patients Start of enrollment: 2021 Jan 04
Publications & Presentations
PubMed
- 35 citationsRisk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide.Annie Im, Armin Rashidi, Tao Wang, Michael T. Hemmer, Margaret L. MacMillan
Biology of Blood and Marrow Transplantation. 2019-03-01 - 31 citationsComposite GRFS and CRFS Outcomes After Adult Alternative Donor HCTRohtesh S. Mehta, Shernan G. Holtan, Tao Wang, Michael T. Hemmer, Stephen R. Spellman
Journal of Clinical Oncology. 2020-05-04 - 5 citationsHigh response rates and transition to transplant after novel targeted and cellular therapies in adults with relapsed/refractory acute lymphoblastic leukemia with Phila...Ibrahim Aldoss, Michelle Afkhami, Dongyun Yang, Zhaohui Gu, Sally Mokhtari
American Journal of Hematology. 2023-06-01
Committees
- Chair, House Staff Quality Council 2014 - 2017
Professional Memberships
- Member
- Member
- Member
- Member
- Member
- Member
Other Languages
- Hindi
Hospital Affiliations
- City of Hope Comprehensive Cancer CenterDuarte, California
- City of Hope Comprehensive Cancer CenterDuarte, California
External Links
- LinkedInhttp://www.linkedin.com/in/vaibhav-agrawal1
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: